Atogepant in Real Life in Italy (GIANT)

Sponsor
IRCCS San Raffaele Roma
Study ID
NCT06136442
Status
Unknown

Conditions

  • Migraine, Prophylaxis

Eligibility Criteria

Sex
ALL
Age
18 Years - 100 Years
Healthy Volunteers
Not accepted

Interventions

  • Atogepant — DRUG
    atogepant in real life in Italy

Study Details

Atogepant is an oral, small-molecule, calcitonin gene-related peptide (CGRP) receptor antagonist that has been approved for the preventive treatment of episodic and chronic migraine (\>= 4 monthly migraine days) with or without medication overuse.

Key Dates

Start date
Apr 9, 2024
Status verified
Jan 2024
Primary completion
Jun 30, 2024
Completion
Dec 31, 2024

Study Design

Enrollment
500 participants (estimated)

Primary Outcome Measure

Change in monthly migraine days at weeks 9-12 compared to baseline [ Time Frame: 12 weeks ]

Central Contacts